Quadrant Capital Group LLC lifted its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 420.3% during the 4th quarter, HoldingsChannel reports. The fund owned 5,541 shares of the company’s stock after acquiring an additional 4,476 shares during the quarter. Quadrant Capital Group LLC’s holdings in Teva Pharmaceutical Industries were worth $80,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. First Republic Investment Management Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 30.1% in the 2nd quarter. First Republic Investment Management Inc. now owns 20,110 shares of the company’s stock worth $489,000 after acquiring an additional 4,657 shares in the last quarter. Virtu Financial LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 665.0% in the 3rd quarter. Virtu Financial LLC now owns 271,537 shares of the company’s stock worth $5,849,000 after acquiring an additional 236,044 shares in the last quarter. Cacti Asset Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 12.5% in the 4th quarter. Cacti Asset Management LLC now owns 577,904 shares of the company’s stock worth $8,911,000 after acquiring an additional 64,180 shares in the last quarter. Handelsbanken Fonder AB acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $485,000. Finally, MetLife Investment Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 12.1% during the 2nd quarter. MetLife Investment Advisors LLC now owns 70,353 shares of the company’s stock worth $1,711,000 after buying an additional 7,600 shares in the last quarter. 61.66% of the stock is currently owned by institutional investors and hedge funds.
TEVA stock opened at $18.82 on Tuesday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. The firm has a market capitalization of $19.14 billion, a PE ratio of 4.79, a P/E/G ratio of 5.98 and a beta of 1.10. Teva Pharmaceutical Industries Ltd has a twelve month low of $14.59 and a twelve month high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.00 EPS. On average, analysts expect that Teva Pharmaceutical Industries Ltd will post 2.83 earnings per share for the current fiscal year.
Several research firms have issued reports on TEVA. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, November 7th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, November 2nd. Royal Bank of Canada set a $22.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, November 2nd. Morgan Stanley raised Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $27.00 in a report on Monday, November 5th. Finally, Bank of America upped their price objective on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “underperform” rating in a report on Friday, November 2nd. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $22.15.
In other news, VP Hafrun Fridriksdottir sold 1,643 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total value of $25,795.10. Following the transaction, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 2,922 shares of company stock worth $53,962. 0.43% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Stake Lifted by Quadrant Capital Group LLC” was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://zolmax.com/investing/teva-pharmaceutical-industries-ltd-teva-stake-lifted-by-quadrant-capital-group-llc/2841248.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: Back-End Load
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.